Gamida Cell is a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Gamida Cell news
10.05.2022
Gamida Cell's IFRS loss for 3 months of 2022 was $20.223 million, up 5.4% from $19.186 million in the previous year.
Source: 
investors.gamida-cell.com
investors.gamida-cell.com
15.03.2022
Gamida Cell's IFRS loss for 2021 was $89.793 million, up 45.8% from $61.573 million the previous year.
Source: investors.gamida-cell.com
investors.gamida-cell.com
15.11.2021
Gamida Cell's IFRS loss for 9M 2021 was $58.964 million, up 45.9% from $40.409 million in the prior year.
Source: investors.gamida-cell.com
investors.gamida-cell.com
11.08.2021
Gamida Cell's IFRS loss for 6M 2021 was $39.33 million, up 53.3% from $25.657 million in the prior year.
Source: investors.gamida-cell.com
investors.gamida-cell.com
General information
| Company name | Gamida Cell |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | PO Box 34670 Jerusalem, 91340 Israel |
| Mailing address | PO Box 34670 Jerusalem, 91340 Israel |
| Website | investors.gamida-cell.com |
| Information disclosure | www.sec.gov |
English (US) 